Pfizer (PFE): 9.5x Adjusted Earnings and a 6.2% Yield
Divide Pfizer‘s price of around $27.66 by the midpoint of its 2026 adjusted earnings guidance of $2.80 to $3.00, and you get roughly 9.5 times earnings. Add a dividend of $1.72 a share, a yield of 6.22%, and the market is describing a business that it expects to shrink. I do not think that is quite right, though I also do not think the case for a rebound is as clean as its fans say.
Two earnings numbers, one stock
The confusion starts with earnings. My data source shows trailing reported earnings of $0.76 a share, which puts the stock at 36.4 times, and consensus forward earnings of $1.94, which gives 14.2 times. The company’s own adjusted guidance of $2.80 to $3.00 gives about 9.5. Three numbers, three multiples, and they cannot all describe the same thing.
Adjusted EPS strips out items management treats as one-off or non-operating, typically acquisition costs and the amortization of acquired intangibles. That is a legitimate way to look at a business that has bought as much as Pfizer has, but the excluded items are real costs paid in real money. I use the adjusted figure as the ceiling on what the stock earns and the reported figure as the floor. The truth for a holder sits between them.
The company reaffirmed the $2.80 to $3.00 range on August 4, and it said the range absorbs a hit of about $0.10 from the Innovent Biologics transaction, according to Pfizer’s second-quarter release filed with the SEC. It also raised the midpoint of 2026 revenue guidance by $500 million, to a range of $60.5 billion to $62.5 billion.
A decline that has already happened
Revenue peaked at $101.2 billion in 2022, when pandemic vaccines and treatments were at full volume. It fell to $59.6 billion in 2023, recovered to $63.6 billion in 2024, and landed at $62.6 billion in 2025, down 2% on the year. The guidance for 2026 brackets that figure, so the drop has largely run its course.
The June quarter fits the pattern. Revenue was $15.0 billion, and adjusted EPS was $0.77. The company said revenue grew 1% on an operational basis. Excluding Comirnaty and Paxlovid, the two pandemic products, operational growth was 5%, and revenue from launched and acquired products grew 18%, per the same release. That last number is the one to watch, because it measures whether the newer portfolio is filling the hole that the old one left.
Margins are steadier than the headlines. Gross margin was 74.3% in the latest fiscal year against 71.9% the year before, and operating income of $17.4 billion on $62.6 billion of revenue is a 28% operating margin. Net income was $7.8 billion against $8.1 billion in 2024. Those are the numbers of a company that is smaller than it was but still highly profitable.
Cost cutting helps.
Pfizer announced an additional $2.5 billion of productivity savings expected to be realized from 2027 through 2029, in the same release. Savings of that size, against a revenue base above $60 billion, add up to about four percent of sales. They do not change the thesis alone, but they cushion it.
| Metric | Value | Context |
|---|---|---|
| Share price | $27.66 | 52-week range $22 to $29 |
| Trailing P/E (reported) | 36.4 | trailing EPS $0.76 |
| Forward P/E (consensus) | 14.2 | forward EPS $1.94 |
| P/E on 2026 adjusted guidance | about 9.5 | $2.80 to $3.00 EPS |
| Dividend yield | 6.22% | $1.72 per share over twelve months |
| Revenue, 2022 vs 2025 | $101.2 billion vs $62.6 billion | 2026 guide $60.5 to $62.5 billion |
| Analyst target (average) | $29 | range $25 to $36, 20 analysts |
The dividend against two payout ratios
The dividend is where the two earnings numbers matter most. On adjusted guidance, $1.72 is about 59% of $2.90, a comfortable payout. On the reported trailing figure of $0.76, the same dividend is more than twice the earnings.
Do the cash math another way. Market value of $157.7 billion at $27.66 a share implies roughly 5.7 billion shares, so the dividend costs the company close to $9.8 billion a year. Against reported net income of $7.8 billion in 2025, that is more than the profit. I would not read that as a cut in waiting, because reported earnings carry charges that the adjusted figure excludes, but it shows why the payout is not the safe thing a 59% ratio makes it look like.
A yield of 6.22% is high enough to be a warning sign in the abstract. I wrote about how a payer this size gets priced in a note on dividend growth versus high yield elsewhere on the site, and the test I use is simple: can the company pay the dividend from what it earns in a normal year without borrowing? For Pfizer, on adjusted numbers, yes. On reported numbers, not by a comfortable margin.
What the pipeline has to do
Pfizer is not priced as if the pipeline works, and I think that is the correct starting point. The company’s own disclosure of launched and acquired products growing 18% is encouraging, but it is measured against a smaller base and it includes acquisitions, so it says less about internal research productivity than it appears to.
I am not going to list individual drug candidates and their odds, because I have not verified trial dates and readout timing and I would rather leave them out than guess. What I can measure is what the pipeline has to deliver in dollars. To hold revenue flat at about $60 billion while patent expirations remove older products, the newer portfolio has to add growth every year. The 5% operational growth excluding the pandemic products is the current proof that this is happening. A quarter where that figure drops below zero would be the first real crack.
There is a useful comparison with Microsoft. In my note on Microsoft at 27.5 times earnings, I argued that a high multiple asks for a specific growth rate. Pfizer’s low multiple asks for the opposite: it prices in the growth rate falling short. The stock only needs modest delivery to look cheap, which is a much easier bar to clear than the one Microsoft has to jump.
Three ways the next two years could go
Start with the cheap version. Suppose adjusted EPS lands at $2.90 and the multiple stays near 9.5. The stock stays near $27.66, and a holder collects the 6.22% yield. That is a return equal to the dividend and nothing else.
Flat, in other words. A stock that goes nowhere but pays 6% is a fine outcome for some people and a boring one for others.
Now the rebound version. If the market decided the business had stabilized and paid 12 times $2.90, the shares would be worth about $35, roughly 26% above today, on top of the dividend. That would still leave Pfizer below the 14.2 times consensus multiple my data source shows, so it does not require a heroic view. It requires the market to trust the adjusted number.
The bad version is the one the low multiple is hedging. If adjusted EPS slid to $2.50 and the multiple stayed at 9.5, the stock would fall to about $24, near the 52-week low of $22, and the dividend would be the only thing softening it. I put the odds of that lower than the other two, but not by much. The downside risk is real, and it is why I call this an income holding and not a bargain.
What analysts think
Of the 20 analysts, 35% rate the stock a Buy. The average target is $29, about 4% above the current price, with a low of $25 and a high of $36. A range of down 10% to up 29% is wider than I would want for a dividend holding, and it tells me the disagreement is real.
The stock is 5.3% below its 52-week high of $29, so it has already bounced, and it is 26% above its low of $22. Recent earnings reactions have been mild: the average move on earnings day is 1.7% and the last report, on August 4, moved the stock +1.5%. That is calm for a company this contested.
The growth number that decides it
One more point on sizing. A holder who treats the 6.22% yield as a bond coupon should remember that a coupon does not get cut when a drug loses patent protection, and a dividend can. I would size the position as if a 20% dividend trim were possible, and check whether the remaining income still justified the shares.
I would rate Pfizer a reasonable place for income and a mediocre place for growth. The 9.5 times multiple on adjusted earnings is cheap only if you accept the adjustments, and the yield is safe only if you accept the same. At $27.66 I would hold it as a slow position and not chase it.
Here is the number that would change my view: operational growth excluding Comirnaty and Paxlovid. At 5% it supports the current price. If it slips below 2% for two quarters in a row, I would stop treating the low multiple as a discount and start treating it as the correct price. If it climbs above 7% while the dividend is held flat, the case for a re-rating becomes hard to argue against.
I would be wrong about the income case if the counter-case plays out. If revenue guidance slips back toward the low end and adjusted EPS falls under $2.80, the payout on adjusted numbers rises toward 61% and the market will stop giving the adjustments the benefit of the doubt.
Analysis and opinion only, not investment advice. Figures come from Pfizer’s filings on SEC EDGAR and its second-quarter release linked above; valuation multiples are approximate and were checked on September 22, 2026.